50. I thank the Ambassador of Sri Lanka for the interest, and very simply note that the report we just delivered is purely on licensing arrangements and announcements that have been made publicly. The analysis of the patent situation is a parallel task, and I might say, a very challenging one, but I certainly agree with the expression of priority given to this by the delegation of the Sri Lanka, since this is a vital area of information. However, we do not have it today at our fingertips. It is a challenging task to get complete, comprehensive, reliable landscaping of the patent situation for any of these vaccines. It includes the platform technologies, where in some cases there are long-standing patents in place, as well as more specific patents on COVID-related developments.
51. This is a constant and fast-evolving picture, however, and in the light of the interest expressed, we would certainly like to work with our colleagues in this regard. This is something that would naturally fall into the category of our cooperation with WIPO and with the World Health Organization. We can certainly take up that interest and we would aim to keep Members up-to-date on this with the usual caveats. Despite it being a challenging task to get complete up-to-date information on the broad situation, it may at least be possible in the coming months to develop at least an overview of the situation, if that is useful to Members. So, while we cannot offer anything immediately, we can certainly undertake to get back to interested delegations with an update, in the next few months.